HC Wainwright Comments on Sensus Healthcare, Inc.’s Q2 2024 Earnings (NASDAQ:SRTS)

Sensus Healthcare, Inc. (NASDAQ:SRTS) – Stock analysts at HC Wainwright lowered their Q2 2024 earnings per share (EPS) estimates for Sensus Healthcare in a report issued on Monday, November 13th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of $0.00 per share for the quarter, down from their prior estimate of $0.01. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Sensus Healthcare’s current full-year earnings is ($0.11) per share.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.08). Sensus Healthcare had a negative return on equity of 1.91% and a negative net margin of 3.58%. The firm had revenue of $3.90 million for the quarter, compared to analysts’ expectations of $6.04 million.

Separately, TheStreet lowered shares of Sensus Healthcare from a “c” rating to a “d+” rating in a research report on Friday.

Sensus Healthcare Trading Up 7.0 %

SRTS stock opened at $2.00 on Tuesday. Sensus Healthcare has a 1 year low of $1.79 and a 1 year high of $9.62. The company has a fifty day simple moving average of $2.49 and a 200 day simple moving average of $2.88. The firm has a market cap of $32.78 million, a PE ratio of -33.33 and a beta of 0.63.

Insiders Place Their Bets

In other Sensus Healthcare news, CEO Joseph C. Sardano acquired 10,000 shares of the business’s stock in a transaction that occurred on Thursday, September 14th. The shares were acquired at an average cost of $2.88 per share, for a total transaction of $28,800.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,175,293 shares of the company’s stock, valued at approximately $3,384,843.84. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 11.10% of the company’s stock.

Institutional Investors Weigh In On Sensus Healthcare

Hedge funds have recently bought and sold shares of the company. Cahill Wealth Management LLC grew its position in shares of Sensus Healthcare by 14.9% in the 1st quarter. Cahill Wealth Management LLC now owns 65,550 shares of the company’s stock valued at $342,000 after acquiring an additional 8,485 shares during the period. Victory Capital Management Inc. grew its position in Sensus Healthcare by 330.6% during the second quarter. Victory Capital Management Inc. now owns 28,024 shares of the company’s stock valued at $88,000 after buying an additional 21,516 shares during the period. Denali Advisors LLC boosted its position in Sensus Healthcare by 414.5% during the second quarter. Denali Advisors LLC now owns 39,100 shares of the company’s stock worth $123,000 after purchasing an additional 31,500 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in Sensus Healthcare by 28.6% in the first quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 192,181 shares of the company’s stock valued at $1,001,000 after purchasing an additional 42,763 shares in the last quarter. Finally, LSV Asset Management bought a new stake in shares of Sensus Healthcare in the 1st quarter worth approximately $285,000. 20.56% of the stock is currently owned by institutional investors and hedge funds.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.